[HTML][HTML] Mechanisms of chemotherapeutic resistance and the application of targeted nanoparticles for enhanced chemotherapy in colorectal cancer

Y Guo, M Wang, Y Zou, L Jin, Z Zhao, Q Liu… - Journal of …, 2022 - Springer
Colorectal cancer is considered one of the major malignancies that threaten the lives and
health of people around the world. Patients with CRC are prone to post-operative local …

[HTML][HTML] Prospects of curcumin nanoformulations in cancer management

H Amekyeh, E Alkhader, R Sabra, N Billa - Molecules, 2022 - mdpi.com
There is increasing interest in the use of natural compounds with beneficial pharmacological
effects for managing diseases. Curcumin (CUR) is a phytochemical that is reportedly …

Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients

S Dihlmann, S Tao, F Echterdiek… - … journal of cancer, 2014 - Wiley Online Library
Functional studies on colorectal cancer cells indicated a protective role of the interferon‐
inducible dsDNA sensor Absent in Melanoma 2 (AIM2) in cancer progression. Given that a …

Tumour budding and survival in stage II colorectal cancer: a systematic review and pooled analysis

F Petrelli, E Pezzica, M Cabiddu, A Coinu… - Journal of …, 2015 - Springer
Purpose Tumour budding is defined as the presence of isolated or small clusters of
malignant cells at the invasive edge of the tumour. It is considered a negative prognostic …

Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq

SV Bratman, AM Newman, AA Alizadeh… - Expert review of …, 2015 - Taylor & Francis
Tumors continually shed DNA into the circulation, where it can be noninvasively accessed.
The ability to accurately detect circulating tumor DNA (ctDNA) could significantly impact the …

Localized colon cancer, version 3.2013

AB Benson, T Bekaii-Saab, E Chan, YJ Chen… - Journal of the National …, 2013 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology for Colon Cancer begin with the clinical
presentation of the patient to the primary care physician or gastroenterologist and address …

[HTML][HTML] Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and …

D Pectasides, V Karavasilis, G Papaxoinis, G Gourgioti… - BMC cancer, 2015 - Springer
Background The aim of the trial was to compare two active adjuvant chemotherapy regimens
in patients with early stage colorectal cancer (CRC). Methods Patients were assigned to …

Systemic treatments for high-risk localized prostate cancer

G Pignot, D Maillet, E Gross, P Barthelemy… - Nature reviews …, 2018 - nature.com
The majority of patients with prostate cancer who later develop lethal metastatic disease
have high-risk localized disease at presentation, emphasizing the importance of effective …

Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy

SH Fang, JE Efron, ME Berho… - Journal of the American …, 2014 - journals.lww.com
In 2013, the American Cancer Society estimated that 102,480 people would be diagnosed
with colon cancer, 1 and approximately one-third of these would be diagnosed with stage II …

[HTML][HTML] Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis

H Yuan, Q Dong, X Hu, JB Xu, S Tu - Oncotarget, 2017 - ncbi.nlm.nih.gov
The prognostic value of lymphovascular invasion (LVI) in stage I/II colorectal cancer (CRC)
does not reach a consensus. To systematically assess prognostic significance of LVI …